25 results on '"Sure, U"'
Search Results
2. Cavernous Sinus Meningiomas: Life-Quality Management
- Author
-
Farhoud, Ahmed, Henzel, M., Sitter, H., Gross, M. W, Sure, U., Engenhart-Cabillic, R., and Bertalanffy, H.
- Published
- 2024
- Full Text
- View/download PDF
3. Surgical Management of Transosseous Dural Arteriovenous Fistulas in the Region of the Jugular Foramen
- Author
-
Tirakotai, Wuttipong, Kappus, C., Krischek, B., Sure, U., and Bertalanffy, H.
- Published
- 2024
- Full Text
- View/download PDF
4. Seizure intractability in patients with mesial temporal lobe epilepsy caused by hippocampal sclerosis as compared to mesiotemporal cavernomas
- Author
-
Hattemer, K, Thiel, P, Haag, A, Chen, X, Benes, L, Hamer, HM, Knake, S, Sure, U, and Rosenow, F
- Published
- 2024
- Full Text
- View/download PDF
5. Risk factors for epilepsy in patients with cavernomas
- Author
-
Chen, X., Heinze, S., Iwinska-Zelder, J., Reuss, A., Dukatz, T., Hattemer, K., Pagenstecher, A., Bertalanffy, H., Rosenow, F., and Sure, U.
- Published
- 2024
- Full Text
- View/download PDF
6. Risk score for early prediction of in-hospital mortality after aneurysmal subarachnoid hemorrhage: pooled analysis with score construction and validation.
- Author
-
Said M, Gümüs M, Darkwah Oppong M, Dömer P, Helgers SOA, Dammann P, Wrede KH, Woitzik J, Sure U, and Jabbarli R
- Abstract
Objective: Aneurysmal subarachnoid hemorrhage (aSAH) has a high complications burden, with in-hospital mortality as most devastating outcome. We aimed to develop and validate a risk score for early prediction of in-hospital mortality after aSAH., Methods: Data from two university hospitals were pooled (n=1070), with cohorts for score construction(n=886) and external validation(n=184). Several parameters assessable at admission were collected. Independent predictors of in-hospital mortality were used as mortality score components. Diagnostic accuracy of the novel score was compared to the HAIR and World Federation of Neurosurgical Societies (WFNS) scores., Results: Overall rate of in-hospital mortality was 19% and 14.7% in construction and validation cohorts, respectively. The novel risk score (aSAH Mortality Score [aSAMS]:0-12 points) included patients' age (≤55 years:0 points, 56-70 years:1 point, >70 years:2 points), aneurysm rebleeding (2 points), WFNS grade (grade I-II:0 points, grade III-IV:2 points, grade V:5 points), and Hijdra sum score (≤10:0 points, 11-20:1 point, 21-30:2 points, >30:3 points). In-hospital mortality rates ranged 0.6% (0 points) -100 % (12 points) in the construction cohort, and 0% (0 points) -60% (10 points) in the validation cohort. In the receiver operating characteristic analysis, the aSAMS score (AUC:0.829 and 0.824 in the construction and validation cohorts, hereinafter) was superior to the HAIR (AUC:0.811 and 0.813) and WFNS scores (AUC:0.768 and 0.795)., Conclusion: Risk of in-hospital mortality after aSAH can be predicted with high accuracy using baseline characteristics. The novel risk score showed best diagnostic performance in the construction and validation cohorts and can aid in early prognostication and treatment decisions., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
7. Risk score for early prognostication of aseptic bone flap necrosis.
- Author
-
Barthel L, Hetze S, Gembruch O, Chihi M, Oppong MD, Ahmadipour Y, Dammann P, Sure U, and Jabbarli R
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Aged, Risk Assessment methods, Young Adult, Surgical Flaps adverse effects, Surgical Flaps pathology, Decompressive Craniectomy adverse effects, Decompressive Craniectomy methods, Postoperative Complications diagnosis, Postoperative Complications etiology, Necrosis etiology
- Abstract
Purpose: Aseptic bone flap necrosis (ABFN) is a common complication of autologous cranioplasty that often requires reoperation. This study aimed to create a risk score for ABFN using relevant demographic, clinical, and laboratory markers., Methods: We included all patients who underwent autologous cranioplasty after decompressive surgery between 2007 and 2019. We collected laboratory data, initial clinical diagnoses, and demographic parameters before autologous bone flap reimplantation. The significant predictors of ABFN identified in the final multivariate analysis were used to develop a risk score., Results: Of the 412 patients who underwent craniectomy, 58 (14%, 32 females: 55.2%) developed ABFN. The following independent predictors of ABFN were included in the risk score (0-7 points): craniectomy due to trauma or hemorrhagic stroke (2 points), younger age (< 40 years, 2 points), cranioplasty timing (> 95 days post-craniectomy, 1 point), glutamate-pyruvate transferase < 18 U/L (1 point), and serum creatinine level < 0.815 mg/dL (1 point). The ABFN rates in patients with scores of 0-2, 3-4, and 5-7 points were 4.2%, 16.1%, and 34.6%, respectively. The risk score demonstrated moderate diagnostic accuracy for predicting ABFN, with an area under the curve of 0.739., Conclusion: The proposed risk score may help in early identification of individuals prone to ABFN. These data suggest that future studies should investigate the significance of metabolic syndromes related to ABFN occurrence. Understanding the potential impact of metabolic factors on ABFN can enhance risk assessment and targeted preventive measures for patients undergoing cranioplasty procedures., Competing Interests: Declarations Ethics approval The local Research Ethics Committee approved the study (24-11849-BO). Consent to participate Informed consent was not required for all patients due to the retrospective design in accordance with local ethics committee protocols. Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Predictors of survival after aneurysmal subarachnoid hemorrhage: The long-term observational cohort study.
- Author
-
Odensass S, Gümüs M, Said M, Rodemerk J, Darkwah Oppong M, Li Y, Ahmadipour Y, Dammann P, Wrede KH, Sure U, and Jabbarli R
- Abstract
Objective: Despite recent advances in neuro-intensive care, there is still considerable mortality in patients with aneurysmal subarachnoid hemorrhage (SAH). In this long-term monocentric observational cohort study, we aimed to analyze the rates, timing, and predictors of mortality after SAH., Methods: All consecutive SAH cases treated between January 2003 and June 2016 were included. Patients' demographic characteristics, previous medical history, SAH-related parameters, and available post-treatment follow-up data were collected and evaluated as potential mortality predictors in univariate and multivariate analyses., Results: Of 992 patients, 179 died during the initial treatment and 33 during the follow-up time reaching an overall mortality rate of 21.4 %. Of over 119 tested variables, we identified the following independent predictors in the final multivariate Cox regression analysis: age >55 years (p<0.0001); World Federation of Neurosurgical Societies (WFNS) admission grade IV or V (p=0.025); Hijdra sum score ≥15 points (p=0.003); intracranial pressure (ICP) increase (p<0.0001); and delayed cerebral ischemia (DCI) (p<0.0001). Being exposed to all five risk factors resulted in the case fatality rate of 75 % within a median survival of 14 days, compared to 2.5 % within a median of 1525 days when none of these features were present., Conclusions: The initial impact of aneurysmal bleeding is amongst the major mortality causes after SAH. Of potentially preventable adverse events, ICP increase and DCI occurring during initial treatment also present eminent clinical relevance for patients' survival in the long-term follow-up. Further ICP and DCI management optimization might help to decrease the mortality rate after SAH., Competing Interests: Declaration of Competing Interest None., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Considerations for future trials in cerebral cavernous malformations.
- Author
-
Cenzato M, Sure U, Lanzino G, Boeris D, Meling T, Regli L, Gruber A, Vajkoczy P, and Lawton M
- Subjects
- Humans, Clinical Trials as Topic methods, Hemangioma, Cavernous, Central Nervous System
- Abstract
Competing Interests: We declare no competing interests.
- Published
- 2024
- Full Text
- View/download PDF
10. Cranioencephalic functional lymphoid units in glioblastoma.
- Author
-
Dobersalske C, Rauschenbach L, Hua Y, Berliner C, Steinbach A, Grüneboom A, Kokkaliaris KD, Heiland DH, Berger P, Langer S, Tan CL, Stenzel M, Landolsi S, Weber F, Darkwah Oppong M, Werner RA, Gull H, Schröder T, Linsenmann T, Buck AK, Gunzer M, Stuschke M, Keyvani K, Forsting M, Glas M, Kipnis J, Steindler DA, Reinhardt HC, Green EW, Platten M, Tasdogan A, Herrmann K, Rambow F, Cima I, Sure U, and Scheffler B
- Subjects
- Humans, Male, Female, Middle Aged, Skull pathology, Bone Marrow pathology, Aged, Adult, Sphingosine-1-Phosphate Receptors metabolism, Glioblastoma pathology, Glioblastoma immunology, Brain Neoplasms pathology, Brain Neoplasms immunology, Receptors, CXCR4 metabolism, Receptors, CXCR4 genetics, CD8-Positive T-Lymphocytes immunology
- Abstract
The ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or nonmalignant intracranial disease to report that the cranial bone (CB) marrow, in juxtaposition to treatment-naive glioblastoma tumors, harbors active lymphoid populations at the time of initial diagnosis. Clinical and anatomical imaging, single-cell molecular and immune cell profiling and quantification of tumor reactivity identified CD8
+ T cell clonotypes in the CB that were also found in the tumor. These were characterized by acute and durable antitumor response rooted in the entire T cell developmental spectrum. In contrast to distal bone marrow, the CB niche proximal to the tumor showed increased frequencies of tumor-reactive CD8+ effector types expressing the lymphoid egress marker S1PR1. In line with this, cranial enhancement of CXCR4 radiolabel may serve as a surrogate marker indicating focal association with improved progression-free survival. The data of this study advocate preservation and further exploitation of these cranioencephalic units for the clinical care of glioblastoma., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
11. Impact of Carotid Siphon Calcification on the Course and Outcome of Patients With Aneurysmal Subarachnoid Hemorrhage.
- Author
-
Engel A, Song L, Rauschenbach L, Gümüs M, Santos AN, Dinger TF, Darkwah Oppong M, Li Y, Gembruch O, Ahmadipour Y, Dammann P, Sure U, and Jabbarli R
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Brain Ischemia diagnostic imaging, Adult, Carotid Artery Diseases diagnostic imaging, Carotid Artery Diseases complications, Treatment Outcome, Carotid Artery, Internal diagnostic imaging, Vascular Calcification diagnostic imaging, Vascular Calcification complications, Endovascular Procedures methods, Aspirin therapeutic use, Calcinosis diagnostic imaging, Retrospective Studies, Subarachnoid Hemorrhage complications, Subarachnoid Hemorrhage diagnostic imaging, Vasospasm, Intracranial diagnostic imaging, Vasospasm, Intracranial etiology
- Abstract
Background: Carotid siphon calcification (CSC) serves as a marker of atherosclerosis and therefore may influence the outcome after subarachnoid hemorrhage (aSAH). We aimed to analyze the impact of CSC on neurological outcomes, ischemia, and vasospasm., Methods: A total of 716 patients with aSAH were treated between December 2004 and June 2016 in our central European tertiary neurovascular care center in Essen, Germany. CSC was recorded using the Woodcock scale (grades 0-3) on a computed tomography scan. Study end points included an unfavorable outcome at 6 months post-aSAH (modified Rankin Scale score ≥4), vasospasm, and early cerebral ischemia (72 hours) and delayed cerebral ischemia (delayed cerebral ischemia; >72 hours) in the follow-up computed tomography scans. The associations were adjusted for patients' baseline characteristics and secondary complications. Finally, within a subgroup analysis, patients with and without daily aspirin intake after endovascular aneurysm occlusion were compared., Results: Increasing grades of CSC were associated with lower rates of vasospasm in the anterior circulation. Severe CSC (grade 3) was independently related to the risk of an unfavorable outcome (adjusted odds ratio [aOR], 4.06 [95% CI, 1.98-8.33]; P <0.001) and early cerebral ischemia (aOR, 1.58 [95% CI, 1.03-2.43]; P =0.035) but not delayed cerebral ischemia (aOR, 1.08 [95% CI, 0.67-1.73]; P =0.763). In the aspirin subgroup analysis, the negative effect of severe CSC on functional outcome remained significant only in aSAH cases without aspirin (aOR, 5.47 [95% CI, 2.38-12.54]; P <0.001). In contrast, there was no association between severe CSC and unfavorable outcomes among individuals with daily aspirin intake (aOR, 0.84 [95% CI, 0.59-4.21]; P =0.603)., Conclusions: Our data suggest CSC as a cerebrovascular risk factor resulting in higher rates of early cerebral ischemia and unfavorable outcomes after aSAH. However, by increasing arterial stiffness, CSC might lower the probability of vasospasm, which could explain the missing link between CSC and delayed cerebral ischemia. Additionally, aspirin intake seems to potentially mitigate the negative impact of CSC on aSAH outcome. Further investigations are needed to confirm the observations from the present study., Competing Interests: None.
- Published
- 2024
- Full Text
- View/download PDF
12. PDCD10 Is a Key Player in TMZ-Resistance and Tumor Cell Regrowth: Insights into Its Underlying Mechanism in Glioblastoma Cells.
- Author
-
Zhu Y, Kim SN, Chen ZR, Will R, Zhong RD, Dammann P, and Sure U
- Subjects
- Humans, Cell Line, Tumor, Gene Expression Regulation, Neoplastic drug effects, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Neoplastic Stem Cells drug effects, Brain Neoplasms pathology, Brain Neoplasms genetics, Brain Neoplasms metabolism, Brain Neoplasms drug therapy, Membrane Proteins metabolism, Membrane Proteins genetics, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins genetics, Cell Proliferation drug effects, DNA Modification Methylases metabolism, DNA Modification Methylases genetics, Tumor Suppressor Proteins metabolism, Tumor Suppressor Proteins genetics, DNA Repair Enzymes metabolism, DNA Repair Enzymes genetics, Glioblastoma pathology, Glioblastoma genetics, Glioblastoma metabolism, Glioblastoma drug therapy, Temozolomide pharmacology, Drug Resistance, Neoplasm genetics, Drug Resistance, Neoplasm drug effects, Apoptosis Regulatory Proteins metabolism, Apoptosis Regulatory Proteins genetics
- Abstract
Overcoming temozolomide (TMZ)-resistance is a major challenge in glioblastoma therapy. Therefore, identifying the key molecular player in chemo-resistance becomes urgent. We previously reported the downregulation of PDCD10 in primary glioblastoma patients and its tumor suppressor-like function in glioblastoma cells. Here, we demonstrate that the loss of PDCD10 causes a significant TMZ-resistance during treatment and promotes a rapid regrowth of tumor cells after treatment. PDCD10 knockdown upregulated MGMT, a key enzyme mediating chemo-resistance in glioblastoma, accompanied by increased expression of DNA mismatch repair genes, and enabled tumor cells to evade TMZ-induced cell-cycle arrest. These findings were confirmed in independent models of PDCD10 overexpressing cells. Furthermore, PDCD10 downregulation led to the dedifferentiation of glioblastoma cells, as evidenced by increased clonogenic growth, the upregulation of glioblastoma stem cell (GSC) markers, and enhanced neurosphere formation capacity. GSCs derived from PDCD10 knockdown cells displayed stronger TMZ-resistance and regrowth potency, compared to their parental counterparts, indicating that PDCD10-induced stemness may independently contribute to tumor malignancy. These data provide evidence for a dual role of PDCD10 in tumor suppression by controlling both chemo-resistance and dedifferentiation, and highlight PDCD10 as a potential prognostic marker and target for combination therapy with TMZ in glioblastoma.
- Published
- 2024
- Full Text
- View/download PDF
13. Exploring potential influencing factors of inadherence to specialist aftercare and long-term medication in patients with acromegaly.
- Author
-
Siegel S, Giese S, Honegger J, Friedel AL, Grzywotz A, Wrede KH, Sure U, Unger N, and Kreitschmann-Andermahr I
- Subjects
- Humans, Male, Female, Middle Aged, Cross-Sectional Studies, Surveys and Questionnaires, Adult, Aged, Acromegaly drug therapy, Aftercare, Medication Adherence
- Abstract
Purpose: To improve the understanding of adherence as one major factor of disease control in acromegaly patients, we systematically assessed patients' motivations to adhere to advised follow-up schedules and recommended medication for acromegaly., Methods: Cross-sectional, postal questionnaire study on adult patients with acromegaly, operated upon a growth hormone producing pituitary adenoma more than 1 year ago in two tertiary treatment centers. We assessed demographic and clinical characteristics, disease status, adherence to acromegaly medication and/or aftercare, and the five dimensions defined by the World Health Organization influencing adherence. Wherever applicable, we included validated short scales. The answers of 63 patients (33 f, 30 m; mean age 56.1 y) were analyzed., Results: Patients with problems in adherence to aftercare had a significantly lower subjective symptomload than those adherent to aftercare (p = 0.026) and a lower perceived need for treatment (p = 0.045). Patients with adherence problems to medication had a higher subjective symptomload than those without (p = 0.056). They also tended to have shorter consultations, were significantly more often dissatisfied with the duration of their medical consultations (42% vs 4.8%, p = 0.019) and tended to find that their physician explained potential difficulties with adherence less well than patients without adherence problems (p = 0.089)., Conclusions: To our knowledge, this is the first study which explored adherence to medication and aftercare in patients with acromegaly, taking into account potential influencing factors from all areas defined by the WHO model of adherence. Of the modifiable factors of adherence, patient-doctor relationship seemed to play a crucial role and could be one leverage point to improve adherence., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Predictors and surgical outcome of hemorrhagic metastatic brain malignancies.
- Author
-
Rauschenbach L, Kolbe P, Engel A, Ahmadipour Y, Oppong MD, Santos AN, Kebir S, Dobersalske C, Scheffler B, Deuschl C, Dammann P, Wrede KH, Sure U, and Jabbarli R
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Prognosis, Treatment Outcome, Adult, Neurosurgical Procedures adverse effects, Risk Factors, Brain Neoplasms secondary, Brain Neoplasms surgery, Brain Neoplasms complications, Cerebral Hemorrhage etiology
- Abstract
Purpose: Intracerebral metastases present a substantial risk of tumor-associated intracerebral hemorrhage (ICH). This study aimed to investigate the risk of hemorrhagic events in brain metastases (BM) from various primary tumor sites and evaluate the safety and outcomes of surgical tumor removal., Methods: A retrospective, single-center review of medical records was conducted for patients who underwent BM removal between January 2016 and December 2017. Patients with hemorrhagic BM were compared to those with non-hemorrhagic BM. Data on preoperative predictors, perioperative management, and postoperative outcomes were collected and analyzed., Results: A total of 229 patients met the inclusion criteria. Melanoma metastases were significantly associated with preoperative hemorrhage, even after adjusting for confounding factors (p = 0.001). Poor clinical status (p = 0.001), larger tumor volume (p = 0.020), and unfavorable prognosis (p = 0.001) independently predicted spontaneous hemorrhage. Importantly, preoperative use of anticoagulant medications was not linked to increased hemorrhagic risk (p = 0.592). Surgical removal of hemorrhagic BM, following cessation of blood-thinning medication, did not significantly affect intraoperative blood loss, surgical duration, or postoperative rebleeding risk (p > 0.096). However, intra-tumoral hemorrhage was associated with reduced overall survival (p = 0.001)., Conclusion: This study emphasizes the safety of anticoagulation in patients with BM and highlights the safety of neurosurgical treatment in patients with hemorrhagic BM when blood-thinning medication is temporarily paused. The presence of intra-tumoral hemorrhage negatively impacts survival, highlighting its prognostic significance in BM patients. Further research with larger cohorts is warranted to validate these findings and elucidate underlying mechanisms., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68 Ga-FAPI-46 PET Data, and Survival Data.
- Author
-
Oster C, Kessler L, Blau T, Keyvani K, Pabst KM, Fendler WP, Fragoso Costa P, Lazaridis L, Schmidt T, Feldheim J, Pierscianek D, Schildhaus HU, Sure U, Ahmadipour Y, Kleinschnitz C, Guberina N, Stuschke M, Deuschl C, Scheffler B, Herrmann K, Kebir S, and Glas M
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Brain Neoplasms diagnostic imaging, Brain Neoplasms metabolism, Brain Neoplasms pathology, Endopeptidases, Gelatinases metabolism, Membrane Proteins metabolism, Positron-Emission Tomography, Prognosis, Quinolines, Serine Endopeptidases metabolism, Survival Analysis, Glioblastoma diagnostic imaging, Glioblastoma metabolism, Glioblastoma pathology, Gliosarcoma diagnostic imaging, Gliosarcoma metabolism, Gliosarcoma pathology
- Abstract
Despite their unique histologic features, gliosarcomas belong to the group of glioblastomas and are treated according to the same standards. Fibroblast activation protein (FAP) is a component of a tumor-specific subpopulation of fibroblasts that plays a critical role in tumor growth and invasion. Some case studies suggest an elevated expression of FAP in glioblastoma and a particularly strong expression in gliosarcoma attributed to traits of predominant mesenchymal differentiation. However, the prognostic impact of FAP and its diagnostic and therapeutic potential remain unclear. Here, we investigate the clinical relevance of FAP expression in gliosarcoma and glioblastoma and how it correlates with
68 Ga-FAP inhibitor (FAPI)-46 PET uptake. Methods: Patients diagnosed with gliosarcoma or glioblastoma without sarcomatous differentiation with an overall survival of less than 2.5 y were enrolled. Histologic examination included immunohistochemistry and semiquantitative scoring of FAP (0-3, with higher values indicating stronger expression). Additionally,68 Ga-FAPI-46 PET scans were performed in a subset of glioblastomas without sarcomatous differentiation patients. The clinical SUVs were correlated with FAP expression levels in surgically derived tumor tissue and relevant prognostic factors. Results: Of the 61 patients who were enrolled, 13 of them had gliosarcoma. Immunohistochemistry revealed significantly more FAP in gliosarcomas than in glioblastomas without sarcomatous differentiation of tumor tissue ( P < 0.0001). In the latter, FAP expression was confined to the perivascular space, whereas neoplastic cells additionally expressed FAP in gliosarcoma. A significant correlation of immunohistochemical FAP with SUVmean and SUVpeak of68 Ga-FAPI-46 PET indicates that clinical tracer uptake represents FAP expression of the tumor. Although gliosarcomas express higher levels of FAP than do glioblastomas without sarcomatous differentiation, overall survival does not significantly differ between the groups. Conclusion: The analysis reveals a significant correlation between SUVmean and SUVpeak in68 Ga-FAPI-46 PET and immunohistochemical FAP expression. This study indicates that FAP expression is much more abundant in the gliosarcoma subgroup of glioblastomas. This could open not only a diagnostic but also a therapeutic gap, since FAP could be explored as a theranostic target to enhance survival in a distinct subgroup of high-risk brain tumor patients with poor survival prognosis., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
16. Determining the cut-off value for the Minimal Documentation System (MIDOS2) screening tool to initiate specialized palliative care based on patient's subjective need for palliative support and symptom burden in inpatients with advanced cancer.
- Author
-
Heinzelmann A, Tewes M, Müller S, Sure U, Herrmann K, Schadendorf D, Warnecke E, Rausch R, Skoda EM, and Salvador Comino MR
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Surveys and Questionnaires, Inpatients, Patient Reported Outcome Measures, Aged, 80 and over, Adult, Documentation methods, Symptom Burden, Palliative Care methods, Neoplasms psychology, Neoplasms therapy, Neoplasms diagnosis
- Abstract
Purpose: The Minimal Documentation System (MIDOS2) is recommended as a systematic screening tool for assessing symptom burden and patient needs in advanced cancer patients. Given the absence of an optimal weighting of individual symptoms and a corresponding cut-off value, this study aims to determine a threshold based on inpatient's subjective need for palliative support. Additionally, we investigate the correlation between symptom burden and subjective need for palliative support collected through a patient-reported outcome measure (PROM) with survival duration of less or more than one year., Methods: Inpatients diagnosed with advanced solid cancer completed an electronic PROM, which included the MIDOS2 questionnaire among other tools. Differences in symptom burden were analysed between patients expressing subjective need for palliative support and those with survival of less or more than one year using ANOVA, Mann-Whitney-U Test, logistic regression, Pearson and Spearman correlation tests. Cut-off analyses were performed using a ROC curve. Youden-Index, sensitivity, and specificity measures were used as well., Results: Between April 2020 and March 2021, 265 inpatients were included in the study. Using a ROC curve, the MIDOS2 analysis resulted in an Area under the curve (AUC) of 0.732, a corresponding cut-off value of eight points, a sensitivity of 76.36% and a specificity of 62.98% in assessing the subjective need for palliative support. The MIDOS2, with double weighting of the significant symptoms, showed a cut-off value of 14 points, achieving a sensitivity of 78.18% and a specificity of 72.38%. A total of 55 patients (20.8%) expressed a need for support from the palliative care team. This need was independent of the oncological tumour entity and increased among patients with a survival of less than one year. These patients reported significantly poorer physical (p < 0.001) or mental (p < 0.001) condition. Additionally, they reported higher intensities of pain (p = 0.002), depressive symptoms (p < 0.001), weakness (p < 0.001), anxiety (p < 0.001), and tiredness (p < 0.001)., Conclusion: Using the established MIDOS2 cut-off value with an adjusted double weighting in our study, a large proportion of inpatients may be accurately referred to SPC based on their subjective need for palliative support. Additionally, subjective reports of poor general, mental, and physical condition, as well as pain, depressive symptoms, weakness, anxiety, and tiredness, increase the subjective need for palliative support, particularly in patients with a survival prognosis of less than one year., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Impact of thyroid hormone replacement therapy on the course and functional outcome of aneurysmal subarachnoid hemorrhage.
- Author
-
Said M, Gümüs M, Rieß C, Dinger TF, Rauschenbach L, Rodemerk J, Chihi M, Darkwah Oppong M, Dammann P, Wrede KH, Sure U, and Jabbarli R
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Treatment Outcome, Hospital Mortality, Adult, Hypothyroidism drug therapy, Retrospective Studies, Cerebral Infarction prevention & control, Cerebral Infarction etiology, Cerebral Infarction drug therapy, Vasospasm, Intracranial etiology, Vasospasm, Intracranial prevention & control, Vasospasm, Intracranial drug therapy, Subarachnoid Hemorrhage drug therapy, Hormone Replacement Therapy methods, Thyroid Hormones therapeutic use
- Abstract
Background: Thyroid hormones were reported to exert neuroprotective effects after ischemic stroke by reducing the burden of brain injury and promoting post-ischemic brain remodeling., Objective: We aimed to analyze the value of thyroid hormone replacement therapy (THRT) due to pre-existing hypothyroidism on the clinical course and outcome of aneurysmal subarachnoid hemorrhage (SAH)., Methods: SAH individuals treated between January 2003 and June 2016 were included. Data on baseline characteristics of patients and SAH, adverse events and functional outcome of SAH were recorded. Study endpoints were cerebral infarction, in-hospital mortality and unfavorable outcome at 6 months. Associations were adjusted for outcome-relevant confounders., Results: 109 (11%) of 995 individuals had THRT before SAH. Risk of intracranial pressure- or vasospasm-related cerebrovascular events was inversely associated with presence of THRT (p = 0.047). In multivariate analysis, THRT was independently associated with lower risk of cerebral infarction (adjusted odds ratio [aOR] = 0.64, 95% confidence interval [CI] = 0.41-0.99, p = 0.045) and unfavorable outcome (aOR = 0.50, 95% CI = 0.28-0.89, p = 0.018), but not with in-hospital mortality (aOR = 0.69, 95% CI = 0.38-1.26, p = 0.227)., Conclusion: SAH patients with THRT show lower burden of ischemia-relevant cerebrovascular events and more favorable outcome. Further experimental and clinical studies are required to confirm our results and elaborate the mechanistic background of the effect of THRT on course and outcome of SAH., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Impact of Vaccination Status on Outcome of Patients With COVID-19 and Acute Ischemic Stroke Undergoing Mechanical Thrombectomy.
- Author
-
Deuschl C, Goertz L, Kabbasch C, Köhrmann M, Kleinschnitz C, Berlis A, Maurer CJ, Mühlen I, Kallmünzer B, Gawlitza M, Kaiser DPO, Klisch J, Lobsien D, Behme D, Thormann M, Flottmann F, Winkelmeier L, Gizewski ER, Mayer-Suess L, Holtmannspoetter M, Moenninghoff C, Schlunz-Hendann M, Grieb D, Arendt CT, Bohmann FO, Altenbernd J, Li Y, Sure U, Mühl-Benninghaus R, Rodt T, Kallenberg K, Durutya A, Elsharkawy M, Stracke CP, Schumann MG, Bock A, Nikoubashman O, Wiesmann M, Henkes H, Dolff S, Demircioglu A, Forsting M, and Styczen H
- Subjects
- Humans, Male, Female, Retrospective Studies, Aged, Middle Aged, Treatment Outcome, SARS-CoV-2, Aged, 80 and over, COVID-19 complications, COVID-19 therapy, COVID-19 mortality, Ischemic Stroke mortality, Ischemic Stroke surgery, Thrombectomy, Vaccination, COVID-19 Vaccines adverse effects
- Abstract
Background: Data on impact of COVID-19 vaccination and outcomes of patients with COVID-19 and acute ischemic stroke undergoing mechanical thrombectomy are scarce. Addressing this subject, we report our multicenter experience., Methods and Results: This was a retrospective analysis of patients with COVID-19 and known vaccination status treated with mechanical thrombectomy for acute ischemic stroke at 20 tertiary care centers between January 2020 and January 2023. Baseline demographics, angiographic outcome, and clinical outcome evaluated by the modified Rankin Scale score at discharge were noted. A multivariate analysis was conducted to test whether these variables were associated with an unfavorable outcome, defined as modified Rankin Scale score >3. A total of 137 patients with acute ischemic stroke (48 vaccinated and 89 unvaccinated) with acute or subsided COVID-19 infection who underwent mechanical thrombectomy attributable to vessel occlusion were included in the study. Angiographic outcomes between vaccinated and unvaccinated patients were similar (modified Thrombolysis in Cerebral Infarction ≥2b: 85.4% in vaccinated patients versus 86.5% in unvaccinated patients; P =0.859). The rate of functional independence (modified Rankin Scale score, ≤2) was 23.3% in the vaccinated group and 20.9% in the unvaccinated group ( P =0.763). The mortality rate was 30% in both groups. In the multivariable analysis, vaccination status was not a significant predictor for an unfavorable outcome ( P =0.957). However, acute COVID-19 infection remained significant (odds ratio, 1.197 [95% CI, 1.007-1.417]; P =0.041)., Conclusions: Our study demonstrated no impact of COVID-19 vaccination on angiographic or clinical outcome of COVID-19-positive patients with acute ischemic stroke undergoing mechanical thrombectomy, whereas worsening attributable to COVID-19 was confirmed.
- Published
- 2024
- Full Text
- View/download PDF
19. Takanori Fukushima 1942 - 2024.
- Author
-
Mathiesen T, Couldwell W, Friedman AH, Lafuente J, Mastronardi L, Meling T, Nonaka Y, Radcliffe L, Sames M, Spetzger U, Sure U, Watanabe K, and Zomorodi A
- Published
- 2024
- Full Text
- View/download PDF
20. Treatment Strategies for Glioblastoma in the Elderly: What Should We Focus on Compared to Younger Patients.
- Author
-
Gull HH, Von Riegen AC, Beckmann GT, Ketelauri P, Walbrodt S, Santos AN, Oster C, Schmidt T, Glas M, Jabbarli R, Özkan N, Dammann P, Scheffler B, Sure U, and Ahmadipour Y
- Abstract
(1) Background: Although the incidence of glioblastoma (GB) has a peak in patients aged 75-84 years, no standard treatment regimen for elderly patients has been established so far. The goal of this study was to analyze the outcome of GB patients ≥ 65 years to detect predictors with relevant impacts on overall survival (OS) and progression-free survival (PFS). (2) Methods: Medical records referred to our institution from 2006 to 2020 were analyzed. Adult GB patients with clinical data, postoperative MRI data, and ≥1 follow-up investigation after surgical resection were included. The complete cohort was divided into a younger (<65) and an elderly group (≥65 years). Multiple factors regarding OS and PFS were scanned using univariate and multivariable regression with p < 0.05. (3) Results: 1004 patients were included with 322 (61.0%) male individuals in the younger and 267 (56.1%) males in the older cohort. The most common tumor localization was frontal in both groups. Gross total resection (GTR) was the most common surgical procedure in both groups, followed by subtotal resection (STR) (145; 27.5%) in the younger group, and biopsy (156; 32.8%) in the elderly group. Multivariate analyses detected that in the younger cohort, MGMT promoter methylation and GTR were predictors for a longer OS, while MGMT methylation, GTR, and hypofractionated radiation were significantly associated with a longer OS in the elderly group. (4) Conclusions: Elderly patients benefit from surgical resection of GB when they show MGMT promoter methylation, undergo GTR, and receive hypofractionated radiation. Furthermore, MGMT methylation seems to be associated with a longer PFS in elderly patients. Further investigations are required to confirm these findings, especially within prospective radiation therapy studies and molecular examinations.
- Published
- 2024
- Full Text
- View/download PDF
21. Histopathological Diagnosis of Primary Central Nervous System Lymphoma after Therapy with Corticosteroids or Anticoagulants.
- Author
-
Feldheim J, Darkwah Oppong M, Feldheim JA, Jabbarli R, Dammann P, Uerschels AK, Gembruch O, Ahmadipour Y, Deuschl C, Junker A, Sure U, and Wrede KH
- Abstract
In patients with primary central nervous system lymphoma (PCNSL), the choice of surgical strategy for histopathologic assessments is still controversial, particularly in terms of preoperative corticosteroid (CS) therapy. To provide further evidence for clinical decision-making, we retrospectively analyzed data from 148 consecutive patients who underwent surgery at our institution. Although patients treated with corticosteroids preoperatively were significantly more likely to require a second or third biopsy ( p = 0.049), it was only necessary in less than 10% of the cases with preoperative (but discontinued) corticosteroid treatment. Surprisingly, diagnostic accuracy was significantly lower when patients were treated with anticoagulation or dual antiplatelet therapy ( p = 0.015). Preoperative CSF sampling did not provide additional information but was associated with delayed surgery ( p = 0.02). In conclusion, preoperative CS therapy can challenge the histological diagnosis of PCNSL. At the same time, our data suggest that preoperative CS treatment only presents a relative contraindication for early surgical intervention. If a definitive diagnosis cannot be made after the first surgical intervention, the timing of a repeat biopsy after the discontinuation of CS remains a case-by-case decision. The effect of anticoagulation and dual antiplatelet therapy on diagnostic accuracy might have been underestimated and should be examined closely in future investigations.
- Published
- 2024
- Full Text
- View/download PDF
22. Longitudinal impact of intracerebral low-grade glioma disease on health-related quality of life.
- Author
-
Rauschenbach L, Bartsch P, Santos AN, Michel A, Gull HH, Ketelauri P, Darkwah Oppong M, Schmidt B, Dobersalske C, Blau T, Ahmadipour Y, Jabbarli R, Wrede KH, Sure U, and Dammann P
- Abstract
Background: The aim of this study was to assess health-related quality of life (HRQOL) before and after treatment for intracerebral low-grade glioma., Methods: Patients with low-grade glioma who underwent surgical tumor removal between 2012 and 2018 were eligible for this study. All individuals and their closest relatives received thorough preoperative (
- Published
- 2024
- Full Text
- View/download PDF
23. Risk factors for poor outcome after aneurysmal subarachnoid hemorrhage in patients with initial favorable neurological status.
- Author
-
Lenkeit A, Oppong MD, Dinger TF, Gümüs M, Rauschenbach L, Chihi M, Ahmadipour Y, Uerschels AK, Dammann P, Deuschl C, Wrede KH, Sure U, and Jabbarli R
- Subjects
- Humans, Middle Aged, Risk Factors, Nimodipine, Cerebral Infarction epidemiology, Cerebral Infarction etiology, Subarachnoid Hemorrhage complications, Subarachnoid Hemorrhage surgery, Hydrocephalus
- Abstract
Background: Aneurysmal subarachnoid hemorrhage (aSAH) remains a devastating diagnosis. A poor outcome is known to be highly dependent on the initial neurological status. Our goal was to identify other parameters that favor the risk of complications and poor outcome in patients with aSAH and initially favorable neurologic status., Methods: Consecutive aSAH cases treated at our hospital between 01/2003 and 06/2016 with the initial World Federation of Neurosurgical Societies grades I-III were included. Data on demographic characteristics, previous medical history, initial aSAH severity, and functional outcome after aSAH were collected. The study endpoints were the occurrence of cerebral infarcts, in-hospital mortality, and unfavorable outcome at 6 months after aSAH (modified Rankin scale > 3)., Results: In the final cohort (n= 582), the rate of cerebral infarction, in-hospital mortality, and unfavorable outcome was 35.1%, 8.1%, and 17.6% respectively. The risk of cerebral infarction was independently related to the presence of acute hydrocephalus (adjusted odds ratio [aOR]=2.33, p<0.0001), aneurysm clipping (aOR=1.78, p=0.003), and use of calcium channel blockers concomitant to nimodipine (aOR=2.63, p=0.002). Patients' age (>55 years, aOR=4.24, p<0.0001), acute hydrocephalus (aOR=2.43, p=0.036), and clipping (aOR=2.86, p=0.001) predicted in-hospital mortality. Baseline characteristics associated with unfavorable outcome at 6 months were age (aOR=2.77, p=<0.0001), Fisher grades III-IV (aOR=2.81, p=0.016), acute hydrocephalus (aOR=2.22, p=0.012), clipping (aOR=3.98, p<0.0001), admission C-reactive protein>1mg/dL (aOR=1.76, p=0.035), and treatment intervals (aOR=0.64 per-5-year-intervals, p=0.006)., Conclusions: Although cerebral infarction is a common complication in aSAH individuals with favorable initial clinical condition, >80% of these patients show favorable long-term outcome. The knowledge of outcome-relevant baseline characteristics might help to reduce the burden of further complications and poor outcome in aSAH patients who tolerated the initial bleeding event well., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
24. The influence of radiological tumor growth pattern on sino‑nasal health in pituitary adenomas.
- Author
-
Walbrodt S, Wrede KH, Chmielewski WX, Dinger TF, Schüβler M, Deuschl C, Chihi M, Gull HH, Jabbarli R, Oppong MD, Lenkeit A, Uerschels AK, Gembruch O, Kreitschmann-Andermahr I, Scheffler B, Sure U, and Ahmadipour Y
- Abstract
Pituitary adenomas are one of the most common mass lesions of the brain and are associated with a reduced quality of life. While transnasal and transsphenoidal endoscopic approaches are considered to deliver similar recovery rates for sino-nasal health (SNH), the impact of radiological tumor growth patterns on SNH has not been evaluated. In the present study, the influence of radiological tumor growth on SNH was examined before and after endoscopic transsphenoidal tumor resection. Patient data were prospectively collected between August 1, 2016 and August 31, 2022. The Knosp and Hardy classifications were used to dichotomize pituitary adenoma lesions into low- and high-graded lesions. SNH was assessed shortly before surgery and at follow-up examinations 3-6 months after operation using the Sino-Nasal Outcome Test for Neurosurgery (SNOT-NC) questionnaire. Fully completed SNOT-NC questionnaires were collected before and after surgery from a total of 101 patients. Independent t-tests showed significantly higher rates of deterioration after surgery in patients with Knosp low-graded lesions compared with those with high-graded tumors for the SNOT-NC total score P=0.048, nasal discomfort P=0.034, sleep problems P=0.024 and visual impairment P=0.042. Pre- and post-operative comparisons for the Knosp low-graded tumor cohort showed an increase of nasal discomfort (P=0.004), while the Knosp high-graded tumor cohort reported decreased visual impairment (P=0.016) after surgery. Assessing the Hardy classification, increased nasal discomfort was reported in patients with high-graded infrasellar tumors after surgery (P=0.046). Growth characteristics of pituitary adenomas based on Knosp and Hardy classifications may influence SNH. Patients with less invasive lesions were revealed to be more prone to experiencing a decrease in SNH, which went beyond the assumed deterioration of 1-3 months. These findings indicate the importance of detailed information regarding SNH as part of every pre-operative patient briefing., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Walbrodt et al.)
- Published
- 2024
- Full Text
- View/download PDF
25. Duration of Intracranial Pressure Increase after Aneurysmal Subarachnoid Hemorrhage: Prognostic Factors and Association with the Outcome.
- Author
-
Ketelauri P, Gümüs M, Gull HH, Said M, Rauschenbach L, Dinger TF, Chihi M, Oppong MD, Ahmadipour Y, Dammann P, Wrede KH, Sure U, and Jabbarli R
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prognosis, Adult, Intracranial Pressure physiology, Retrospective Studies, Time Factors, Treatment Outcome, Risk Factors, Intracranial Aneurysm complications, Intracranial Aneurysm surgery, Subarachnoid Hemorrhage complications, Intracranial Hypertension etiology
- Abstract
Objective: A rupture of the intracranial aneurysm is frequently complicated, with an increase of intracranial pressure (ICP) requiring conservative and/or surgical treatment. We analyzed the risk factors related to the duration of pathologic ICP increase and the relationship between ICP burden and the outcome of subarachnoid hemorrhage (SAH)., Methods: Consecutive cases with aneurysmal SAH treated at our institution between 01/2003 and 06/2016 were eligible for this study. Different admission variables were evaluated to predict the duration of ICP increase >20 mmHg in univariate and multivariate analyses. The association of the ICP course with SAH outcome parameters (risk of cerebral infarction, in-hospital mortality, and unfavorable outcome at 6 months defined as modified Rankin scale >3) was adjusted for major outcome-relevant confounders., Results: Of 820 SAH patients, 378 individuals (46.1%) developed at least one ICP increase requiring conservative and/or surgical management after aneurysm treatment (mean duration: 1.76 days, range: 1 - 14 days). In the multivariable linear regression analysis, patients' age (unstandardized coefficient [UC]=-0.02, p <0.0001), World Federation of Neurosurgical Societies (WFNS) grade 4-5 at admission (UC=0.71, p <0.004), regular medication with the angiotensinconverting enzyme (ACE) inhibitors (UC=-0.61, p =0.01), and presence of intracerebral hemorrhage (UC=0.59, p =0.002) were associated with the duration of ICP increase. In turn, patients with longer ICP elevations were at higher risk for cerebral infarction (adjusted odds ratio [aOR]=1.32 per-day-increase, p <0.0001), in-hospital mortality (aOR=1.30, p <0.0001) and unfavorable outcome (aOR=1.43, p <0.0001). SAH patients who underwent primary decompressive craniectomy (DC) showed shorter periods of ICP increase than patients with a secondary decompression (mean: 2.8 vs 4.9 days, p <0.0001)., Conclusion: The duration of ICP increase after aneurysm rupture is a strong outcome predictor and is related to younger age and higher initial severity of SAH. Further analysis of the factors impacting the course of ICP after SAH is essential for the optimization of ICP management and outcome improvement., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.